Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for China SXT Pharmaceuticals's Dividend Yield % or its related term are showing as below:
FRA:2RY1's Dividend Yield % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.97 * Ranked among companies with meaningful Dividend Yield % only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
China SXT Pharmaceuticals (FRA:2RY1) Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:2RY1 vs CABR, BFRI, BIOE: Dividend Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, China SXT Pharmaceuticals's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China SXT Pharmaceuticals Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China SXT Pharmaceuticals's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where China SXT Pharmaceuticals's Dividend Yield % falls into.
China SXT Pharmaceuticals (FRA:2RY1) has a Dividend Yield % of 0.00% as of Jul. 25, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on China SXT Pharmaceuticals and its competitors. According to the industry distribution chart, China SXT Pharmaceuticals ranks #999999 out of 513 companies in the Drug Manufacturers industry.
Is China SXT Pharmaceuticals' Dividend Yield % too high?
China SXT Pharmaceuticals' current Dividend Yield % is 0.00%. Based on the distribution chart, China SXT Pharmaceuticals ranks #999999 out of 513 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, China SXT Pharmaceuticals has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does China SXT Pharmaceuticals' Dividend Yield % compare to CABR and BFRI?
According to the Drug Manufacturers industry distribution chart, China SXT Pharmaceuticals ranks #999999 out of 513 companies for Dividend Yield %. This places China SXT Pharmaceuticals in the lower half of its industry. The industry median Dividend Yield % is 1.97. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Drug Manufacturers company?
The median Dividend Yield % among Drug Manufacturers companies is 1.97, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on China SXT Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Dividend Yield % is 1.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China SXT Pharmaceuticals's current Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China SXT Pharmaceuticals stock overvalued right now?
China SXT Pharmaceuticals (FRA:2RY1) has a current Dividend Yield % of 0.00%. The stock's GF Value™ is €1.16, compared to a current price of €0.04 — trading 96.9% below its estimated fair value. The current Dividend Yield % is 0.00%. China SXT Pharmaceuticals' overall GF Score™ is 40/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For China SXT Pharmaceuticals (FRA:2RY1), the current Dividend Yield % is 0.00% as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China SXT Pharmaceuticals (FRA:2RY1) Overvalued in 2026?
Based on GuruFocus' analysis, China SXT Pharmaceuticals stock appears to be undervalued.
The current stock price of €0.04 is trading 96.9% below its estimated GF Value™ of €1.16.
Key valuation signals for FRA:2RY1:
Dividend Yield %: 0.00%
GF Value™: €1.16 vs. price of €0.04 (96.9% below fair value)
No single metric tells the full story. See the FRA:2RY1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.
40GF Score
Get the complete analysis for FRA:2RY1
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2RY1 has been successfully added to your 
